Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

NCT03610724 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Tisagenlecleucel
DRUG: lymphodepleting chemotherapy
DRUG: Bridging Therapy

Sponsor

Novartis Pharmaceuticals